Toggle Nav
Advanced Search
My Cart

Shop by Category

View all Hematology titles
End of Year Sale. Save up to thirty five percent off sitewide.End of Year Sale. Save up to thirty five percent off sitewide.

Chronic Lymphocytic Leukemia, An Issue of Hematology/Oncology Clinics of North America, 1st Edition

Editor :
Jennifer R. Brown︎
This issue of Hematology/Oncology Clinics, guest edited by Dr. Jennifer R. Brown?, will focus on Chronic Lymphocytic Leukemia. This issue is one of six selected each year by our series consulting editors, Dr. George P. Canellos and Dr. Edward J. Benz ...view more

This issue of Hematology/Oncology Clinics, guest edited by Dr. Jennifer R. Brown?, will focus on Chronic Lymphocytic Leukemia. This issue is one of six selected each year by our series consulting editors, Dr. George P. Canellos and Dr. Edward J. Benz. Topics discussed in this issue will include: Chronic Lymphocytic Leukemia: Do We Know the Cell of Origin Yet?; Significance of BCR Stereotypy; Prognostic and Predictive Implications of Cytogenetics and Genomics; Role of Epigenetics in Chronic Lymphocytic Leukemia; Genomics of Resistance to Targeted Therapies; First Line Therapy for Chronic Lymphocytic Leukemia; The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia Therapy; BTK Inhibitors; Minimal Residual Disease; Should Undetectable MRD Be the Goal of Chronic Lymphocytic Leukemia Therapy?; Management of Chronic Lymphocytic Leukemia after Progression on BTK Inhibitors; Role of PI3K Inhibitors in Chronic Lymphocytic Leukemia; Can We Restore the Immunodeficiency of Chronic Lymphocytic Leukemia?; and Immune Therapy for Chronic Lymphocytic Leukemia

Be the first to review this product
printebook
Special Price $87.19 $108.99
printebook
Special Price $87.19 $108.99
Add to Cart
Add to Cart
Subscription Options
Add to Wish List
PRINT ON DEMAND - DELIVERY CAN TAKE UP TO 10 DAYS
20% OFF
main product photo

This issue of Hematology/Oncology Clinics, guest edited by Dr. Jennifer R. Brown?, will focus on Chronic Lymphocytic Leukemia. This issue is one of six selected each year by our series consulting editors, Dr. George P. Canellos and Dr. Edward J. Benz. Topics discussed in this issue will include: Chronic Lymphocytic Leukemia: Do We Know the Cell of Origin Yet?; Significance of BCR Stereotypy; Prognostic and Predictive Implications of Cytogenetics and Genomics; Role of Epigenetics in Chronic Lymphocytic Leukemia; Genomics of Resistance to Targeted Therapies; First Line Therapy for Chronic Lymphocytic Leukemia; The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia Therapy; BTK Inhibitors; Minimal Residual Disease; Should Undetectable MRD Be the Goal of Chronic Lymphocytic Leukemia Therapy?; Management of Chronic Lymphocytic Leukemia after Progression on BTK Inhibitors; Role of PI3K Inhibitors in Chronic Lymphocytic Leukemia; Can We Restore the Immunodeficiency of Chronic Lymphocytic Leukemia?; and Immune Therapy for Chronic Lymphocytic Leukemia


Author Information
Edited by Jennifer R. Brown?, MD, PhD, Professor of Medicine, Harvard Medical School,Director of CLL Center, Dana-Farber Cancer Institute
Table Of Contents

* Elsevier is a leading publisher of health science books and journals, helping to advance medicine by delivering superior education, reference information and decision support tools to doctors, nurses, health practitioners and students. With titles available across a variety of media, we are able to supply the information you need in the most convenient format.



Copyright © 2024, its licensors, and contributors.

All rights are reserved, including those for text and data mining, AI training, and similar technologies.

For problems or suggestions regarding this site, please visit our Support Hub.

RELX Group